AlzeCure Pharma获得2.5百万欧元用于在新的临床试验中推广其实验性阿尔茨海默氏病药物。 AlzeCure Pharma gets €2.5M to advance its experimental Alzheimer’s drug in a new clinical trial.

AlzeCure Pharma收到了首笔250万欧元的EIC加速器赠款,用于资助其实验性阿尔茨海默氏病药物ACD856的第二阶段a临床试验。 AlzeCure Pharma has received the first €2.5 million installment of an EIC Accelerator grant to fund a Phase IIa clinical trial of its experimental Alzheimer’s drug, ACD856. 该化合物,Trk-PAM, 瞄准大脑信号路径 连接到认知和神经防护。 The compound, a Trk-PAM, targets brain signaling pathways tied to cognition and neuroprotection. 早期的数据显示它安全到达大脑 激活与记忆和情绪有关的电路 Earlier data show it safely reaches the brain and activates circuits involved in memory and mood. 这笔资金支持进一步发展药物候选者,这是更广泛的神经病(包括帕金森氏病和创伤性脑损伤)的管道的一部分。 The funding supports further development of the drug candidate, part of a broader pipeline for neurological conditions including Parkinson’s and traumatic brain injury.